Dahl Morten, Bowler Russell P, Juul Klaus, Crapo James D, Levy Samuel, Nordestgaard Børge G
Department of Clinical Biochemistry and Copenhagen General Population Study, Herlev Hospital and Copenhagen University Hospital, Copenhagen, Denmark.
Am J Respir Crit Care Med. 2008 Nov 1;178(9):906-12. doi: 10.1164/rccm.200804-549OC. Epub 2008 Aug 14.
Superoxide dismutase (SOD) 3 inhibits oxidative fragmentation of lung matrix components collagen I, hyaluronan, and heparan sulfate. Inherited change in SOD3 expression or function could affect lung matrix homeostasis and influence pulmonary function.
To identify novel SOD3 polymorphisms that are associated with lung function or chronic obstructive pulmonary disease (COPD).
Resequencing of 182 individuals identified two novel polymorphisms, E1 (rs8192287) and I1 (rs8192288), in a conserved region of the SOD3 gene of potential relationship to lung function. We next genotyped 9,093 individuals from the Copenhagen City Heart Study for the polymorphisms and recorded spirometry, and admissions and deaths due to COPD during 26-year follow-up. Finally, we validated our findings in a cross-sectional analysis of 35,635 individuals from the Copenhagen General Population Study.
Genotyping the Copenhagen City Heart Study identified 35 E1/I1 homozygotes, 1,050 heterozygotes, and 8,008 noncarriers (Hardy-Weinberg equilibrium: P = 0.93). Using quadruple lung function measurements, we found that E1/I1 homozygotes had 7% lower FVC % predicted (P = 0.006) and 4% lower FEV(1) % predicted (P = 0.12) compared with noncarriers. In the Copenhagen General Population Study, E1/I1 homozygotes also had lower FVC % predicted than noncarriers (P = 0.03), confirming an association between E1/I1 genotype and reduced lung function. E1/I1 homozygotes had adjusted hazard ratios for COPD hospitalization and COPD mortality of 2.5 (95% confidence interval, 1.0-5.9) and 3.7 (95% confidence interval, 0.9-15), respectively; the results were independent of influence from the R213G allele of the SOD3 gene.
We identified two novel polymorphisms in a conserved region of the SOD3 gene and show that individuals that are homozygous for these polymorphisms have reduced FVC % predicted in two large, population-based studies.
超氧化物歧化酶(SOD)3可抑制肺基质成分胶原蛋白I、透明质酸和硫酸乙酰肝素的氧化片段化。SOD3表达或功能的遗传性改变可能影响肺基质稳态并影响肺功能。
鉴定与肺功能或慢性阻塞性肺疾病(COPD)相关的新型SOD3多态性。
对182名个体进行重测序,在SOD3基因的一个保守区域发现了两个新型多态性位点,即E1(rs8192287)和I1(rs8192288),它们可能与肺功能有关。接下来,我们对哥本哈根市心脏研究中的9093名个体进行了这两个多态性位点的基因分型,并记录了肺活量测定结果,以及在26年随访期间因COPD的入院和死亡情况。最后,我们在对哥本哈根普通人群研究中的35635名个体进行的横断面分析中验证了我们的发现。
对哥本哈根市心脏研究进行基因分型,发现35名E1/I1纯合子、1050名杂合子和8008名非携带者(哈迪-温伯格平衡:P = 0.93)。使用四项肺功能测量指标,我们发现与非携带者相比,E1/I1纯合子的预测FVC%降低了7%(P = 0.006),预测FEV(1)%降低了4%(P = 0.12)。在哥本哈根普通人群研究中,E1/I1纯合子的预测FVC%也低于非携带者(P = 0.03),证实了E1/I1基因型与肺功能降低之间的关联。E1/I1纯合子因COPD住院和COPD死亡的调整后风险比分别为2.5(95%置信区间,1.0 - 5.9)和3.7(95%置信区间,0.9 - 15);结果不受SOD3基因R213G等位基因影响。
我们在SOD3基因的一个保守区域鉴定出两个新型多态性位点,并表明在两项基于人群的大型研究中,这些多态性位点的纯合个体预测FVC%降低。